Boston Scientific Co. (NYSE:BSX) CFO Daniel J. Brennan Sells 15,087 Shares

Boston Scientific Co. (NYSE:BSX) CFO Daniel J. Brennan sold 15,087 shares of the company’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the completion of the transaction, the chief financial officer now directly owns 241,451 shares in the company, valued at $25,369,256.57. This represents a 5.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Boston Scientific Trading Up 0.1 %

Shares of NYSE:BSX opened at $106.20 on Friday. The stock has a market capitalization of $156.51 billion, a PE ratio of 84.96, a P/E/G ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 1 year low of $65.33 and a 1 year high of $107.17. The firm has a fifty day moving average price of $96.11 and a 200 day moving average price of $87.97. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Analysts expect that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Institutional Investors Weigh In On Boston Scientific

A number of hedge funds have recently bought and sold shares of the company. Gallagher Fiduciary Advisors LLC boosted its holdings in Boston Scientific by 13.0% during the fourth quarter. Gallagher Fiduciary Advisors LLC now owns 6,985 shares of the medical equipment provider’s stock valued at $624,000 after acquiring an additional 802 shares during the period. Wahed Invest LLC boosted its holdings in Boston Scientific by 6.3% during the fourth quarter. Wahed Invest LLC now owns 37,921 shares of the medical equipment provider’s stock valued at $3,387,000 after acquiring an additional 2,242 shares during the period. Itau Unibanco Holding S.A. bought a new stake in Boston Scientific during the fourth quarter valued at about $43,000. Keel Point LLC boosted its holdings in Boston Scientific by 12.0% during the fourth quarter. Keel Point LLC now owns 4,276 shares of the medical equipment provider’s stock valued at $382,000 after acquiring an additional 457 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec boosted its holdings in Boston Scientific by 7.4% during the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 1,832,594 shares of the medical equipment provider’s stock valued at $163,687,000 after acquiring an additional 126,837 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft raised Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price target on the stock in a report on Friday, January 10th. Morgan Stanley upped their price target on Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. TD Cowen upped their price target on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Royal Bank of Canada upped their price target on Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a report on Thursday, February 6th. Finally, Piper Sandler boosted their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $107.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.